Renal cell carcinoma is the most common type of kidney cancer in adults. It
accounts for approximately 3% of adult malignancies and 90–95% of neoplasms
arising from the kidney. At the moment several biological agents are used for
the treatment of metastatic renal cell carcinoma. We describe the case of a man
who has been treated with pazopanib (Votrient) for metastatic renal cell
carcinoma since July 2011. At the time of writing, the patient is still
receiving treatment (29 months) and is showing a long-lasting response with a
favorable safety profile. This is an excellent example of chronic neoplastic
disease in a patient who can be defined as long-surviving.
van SpronsenD.J., de WeijerK.J., MuldersP.F., De MulderP.H.: Novel treatment
strategies in clear-cell metastatic renal cell carcinoma.Anticancer Drugs, 16:
709–717, 2005.
5.
AtkinsM., ReganM., McDermottD.: Update on the role of
interleukin 2 and other cytokines in the treatment of patients with stage IV
renal carcinoma.Clin Cancer Res, 10:
6342S–6346S,
2004.
6.
CalabròF., SternbergC.N.: Novel targeted
therapy for advanced renal carcinoma: trials in progress.Curr Opin Urol, 20:
382–387, 2010.
EscudierB., PluzanskaA., KoralewskiP., RavaudA., BracardaS., SzczylikC., ChevreauC., FilipekM., MelicharB., BajettaE., GorbunovaV., BayJ.O., BodrogiI.,
Jagiello-GruszfeldA., MooreN.; AVOREN Trial investigators:
Bevacizumab plus interferon alfa-2a for treatment of
metastatic renal cell carcinoma: a randomised, double-blind phase III
trial.Lancet, 370:
2103–2111, 2007.
12.
HudesG., CarducciM., TomczakP., DutcherJ., FiglinR., KapoorA., StaroslawskaE., SosmanJ., McDermottD., BodrogiI., KovacevicZ., LesovoyV., Schmidt-WolfI.G., BarbarashO., GokmenE., O'TooleT., LustgartenS., MooreL., MotzerR.J.; Global ARCC Trial:
Temsirolimus, interferon alfa, or both for advanced
renal-cell carcinoma.N Engl J Med, 356:
2271–2281, 2007.
13.
MotzerR., EscudierB., OudardS., HutsonT., PortaC., BracardaS., GrünwaldV., ThompsonJ.A., FiglinR.A., HollaenderN., UrbanowitzG., BergW.J., KayA., LebwohlD., RavaudA.; RECORD1 Study Group:
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III
trial.Lancet, 372:
449–456, 2008.
14.
HurwitzH., DowlatiA., SavageS.: Safety, tolerability
and pharmacokinetics of oral administration of GW786034 in pts with solid
tumors.J Clin Oncol, 23: 195s,
2012.
15.
HutsonT., DavisI., MachielsJ.: Predictive and
prognostic factors in phase II renal cell carcinoma trial with pazopanib
(GW786034), a multi-kinase angiogenesis inhibitor.Ann Oncol, 19: (suppl 8); abstr
5780, 2008.
16.
HutsonT.E., DavisI.D., MachielsJ.H.: Biomarker analysis
and final efficacy and safety results of a phase II renal cell carcinoma
trial with pazopanib (GW786034), a multi-kinase angiogenesis
inhibitor.J Clin Oncol, 26: 261s (abstr
5046), 2008.
17.
MotzerR., HutsonT., ReevesJ., HawkinsR., GuoJ., NathanP., StaehlerM., De SouzaP., MerchanJ.R., FifeK., JinJ., JonesR., UemuraH., De GiorgiU., HarmenbergU., WangJ., CellaD., McCannL., DeenK., ChoueriT.K.: Randomized,
open-label, phase III trial of pazopanib versus sunitinib in first-line
treatment of patients with metastatic renal cell carcinoma (mRCC): results
of the COMPARZ trial.Ann Oncol23 (Suppl 9): abstr 2325,
2012.
18.
EscudierB., PortaC., BonoP., GiorgiU., ParikhO., HawkinsR.: Patient preference
between pazopanib (Paz) and sunitinib (Sun): results of a randomized
double-blind, placebo-controlled, cross-over study in patients with
metastatic renal cell carcinoma (mRCC) – PISCES study, NCT
01064310.J Clin Oncol, 30(Suppl 15):
CRA4502, 2012.
